Table 4.

Baseline characteristics and treatment effects between Group 2 and BRAVO 12 months trial.

	Group 2 (first Bevacizumab and then Ranibizumab or all Ranibizumab) n = 7	BRAVO 12 months trial N = 131	P value*
Average amount of IVI	3.86 (1.95)	8.4 (–)†	–
Average initial BCVA, ETDRS letter score, mean(SD)	55.43 (20.92)	53.0 (12.5)	P = .77
Average BCVA improvement, ETDRS letter score, mean (SD)	18.43 (16.95)	18.3 (14.89)	P = .98
Average initial CRT, μm, mean (SD)	548.29 (231.64)	551.7 (223.5)	P = .97
Average CRT improvement, μm, mean (SD)	262.43 (197.38)	347.4 (–)†	–

^*Two sample t test.

^†Inadequate information to obtain standard deviation.

BCVA = best corrected visual acuity; CRT = central retinal thickness; IVI = intravitreal injection, SD = standard deviations.